Is polymyositis or dermatomyositis in patients with rheumatoid arthritis induced or unveiled by anti-tumor necrosis factor treatment?
Nagashima
Takao
T
Minota
Seiji
S
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000139:chemically induced / Q000150:complications* / Q000188:drug therapy*; D003882:Dermatomyositis / Q000139:chemically induced / Q000150:complications*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D017285:Polymyositis / Q000139:chemically induced / Q000150:complications*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept
Rheumatol Int. 2011 May;31(5):705-6
20352218
Rheumatol Int. 2001 Apr;20(3):119-23
11354559
Medicine (Baltimore). 2007 Jul;86(4):242-251
17632266
Mod Rheumatol. 2006;16(6):410-1
17165006
J Rheumatol. 2006 Jan;33(1):24-30
16395746
Rheumatol Int. 2009 Aug;29(10):1261-2
19142639
Clin Rheumatol. 2000;19(5):371-7
11055826
Q J Med. 1990 Oct;77(282):1019-38
2267280
J Rheumatol. 2008 Oct;35(10):2074-6
18843765
Clin Rheumatol. 2010 May;29(5):563-6
20143116